home / stock / snse / snse news

SNSE News and Press, Sensei Biotherapeutics Inc. From 02/21/23

Stock Information
Company Name: Sensei Biotherapeutics Inc.
Stock Symbol: SNSE
Market: NASDAQ
Website: senseibio.com
Menu
SNSE SNSE Quote SNSE Short SNSE News SNSE Articles SNSE Message Board
Get SNSE Alerts

News, Short Squeeze, Breakout and More Instantly...
SNSE - Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Keystone Symposia on Next Generation Antibody Therapeutics

BOSTON, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, presented preclinical data on SNS-101, a conditionally active, pH-selective VISTA-blockin...
SNSE - Sensei Biotherapeutics to Participate in Citi's 2023 Virtual Oncology Leadership Summit

BOSTON, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, today announced that Company management will participate in a fireside chat at Citiȁ...

SNSE - Sensei Biotherapeutics to Present New Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Keystone Symposia on Next Generation Antibody Therapeutics

BOSTON, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, will present new preclinical data on SNS-101, a conditionally active, pH-selective VISTA-...

SNSE - Sensei Biotherapeutics Signs Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to Expand Development Plan for SNS-101, a Conditionally Active VISTA-blocking Antibody

BOSTON, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that it has signed a Cooperative Research and Development Agreement (CRAD...
SNSE - Sensei Biotherapeutics Announces Clinical Supply Agreement with Regeneron for Phase 1/2 Clinical Trial Evaluating SNS-101, a Conditionally Active VISTA-blocking Antibody, in Combination with Libtayo® (cemiplimab) in Solid Tumors

BOSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer, today announced a clinical supply agreement with Regeneron for its anti-PD1 therapy Libtayo ...

SNSE - Newman Ferrara LLP Announces Corporate Governance Investigations of Sensei Biotherapeutics, Inc. (SNSE)

Newman Ferrara LLP announced today that the firm is conducting investigations on behalf of shareholders of Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) (“Sensei” or the “Company”). The investigations concern whether certain of the Sensei’s officers and directors b...

SNSE - Sensei to shut Boston research site, cut workforce by ~40%

Sensei Biotherapeutics ( NASDAQ: SNSE ) said it will close its research site in Boston and reduce its total workforce by ~40%. The company added that it will focus resources on its key programs, including its lead antibody SNS-101, and other TMAb (Tumor Microenvironment Activ...
SNSE - Sensei Biotherapeutics Provides Update on Strategic Priorities

- Closes Boston research site, reducing workforce by approximately 40 percent to decrease operating expenses - - Continued focus on development of TMAb™ programs; IND submission for lead antibody SNS-101 anticipated in or prior to April 2023 - - Cash runway extended into ...

SNSE - Sensei Biotherapeutics to Participate in the Piper Sandler 34th Annual Healthcare Conference

BOSTON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that John Celebi, President and Chief Executive Officer, will parti...

SNSE - Sensei Biotherapeutics Announces Collaboration with Washington University, St. Louis to Support Development of SNS-101, a Conditionally Active VISTA-blocking Antibody

BOSTON, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced it has entered into a Sponsored Research Agreement with Washington ...
Previous 10 Next 10